NovoCure Ltd — Director's Dealing 2020

Jan 25, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2020-01-22

Reporting Person: GROENHUYSEN WILHELMUS CM (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-22	Ordinary Shares	M	1515	$7.03	Acquired	88858	Direct
2020-01-22	Ordinary Shares	S	1515	$98.107	Disposed	87343	Direct
2020-01-22	Ordinary Shares	M	1400	$7.03	Acquired	88743	Direct
2020-01-22	Ordinary Shares	S	1400	$98.18	Disposed	87343	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-22	Options to Buy Ordinary Shares	$7.03	M	1515	Acquired	2023-02-19	Ordinary Shares (1515.0)	Direct
2020-01-22	Options to Buy Ordinary Shares	$7.03	M	1400	Acquired	2023-02-19	Ordinary Shares (1400.0)	Direct

Footnotes

F1: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen.

F2: On January 22, 2020, Mr. Groenhuysen sold 1,515 shares in multiple trades at prices ranging from $97.80 to $98.73. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

F3: On January 22, 2020, Mr. Groenhuysen sold 1,400 shares in multiple trades at prices ranging from $97.89 to $98.73. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

F4: Fully vested as of the date hereof.